Zydus gets USFDA nod for Lamotrigine extended-release tablets
Zydus Cadila announced that it has received approval from the United States Food and Drug Administration (USFDA) to market Lamotrigine extended-release tablets USP in the strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg and 300 mg.
The medication indicated is used in the treatment for certain types of seizures and will be manufactured at the group’s manufacturing facility at Ahmedabad’s special economic zone (SEZ).
Zydus Cadila now has around 283 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare Limited manufactures and markets healthcare solutions ranging from formulations, active pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to cosmeceuticals. Its products are available in tablets, capsules, injections, liquids, dry syrups, powders, granules and ointments.
At 12.40 pm on Friday, the stock was trading at Rs 271.85, up by 3.03 per cent or Rs 8 per share. The 52-week high is recorded at Rs 350.05 and the 52-week low is Rs 206.45 on BSE.